CONFERENCE INFORMATION

SUMMIT DESCRIPTION

The 2026 Masters in Therapeutic Oncology Summit – Breast Edition (MaTOS Breast) is the premier educational event designed to address identified practice gaps and support continuous professional development in the evolving landscape of breast cancer care. This summit will provide clinicians, researchers, and care teams with evidence-based strategies and practical tools to improve patient outcomes through enhanced knowledge, competence, and performance.

Through a blend of clinical science sessions, expert-led panels, roundtable discussions, and real-world case presentations, the summit will address pressing challenges in breast oncology, including:

Genetic and epigenomic underpinnings of disease
Diagnosis and minimal residual disease (MRD) monitoring
Integration of targeted therapies and immunotherapy
Evaluation of therapeutic response using novel technologies
Application of precision oncology in treatment planning
Innovations in surgical and radiological de-escalation for early-stage disease

The summit will foster multidisciplinary collaboration among key opinion leaders (KOLs), senior investigators, and attendees, enabling a critical review of current and emerging practices in breast cancer screening, diagnostics, and treatment. Discussions will emphasize how new therapies and technologies are shaping standards of care, and will guide attendees in interpreting clinical data, adopting biomarker-driven approaches, and navigating rapidly evolving therapeutic landscapes.

By integrating innovative educational strategies, MaTOS Breast will empower healthcare professionals to make informed, patient-centered decisions, implement practice-changing innovations in breast cancer management and foster collaboration among stakeholders in the field.

LEARNER OBJECTIVES

At the conclusion of this summit, participants will be better able to:

Describe recent advancements in breast cancer genomics and epigenomics, and their application in diagnosis, prognosis, MRD detection, and response monitoring, including implications for patient stratification and individualized treatment.

Evaluate emerging targeted therapies and immunotherapies—including PI3K/AKT/mTOR inhibitors, estrogen receptor modulators, and antibody-drug conjugates—and integrate this knowledge into evidence-informed clinical decision-making.

Compare current and future approaches to breast cancer screening and surveillance, including the clinical utility of liquid biopsy, next-generation sequencing, and imaging modalities, and assess their role in early detection and ongoing monitoring.

Assess the impact of precision oncology and biomarker-driven strategies on treatment planning and identify ways to incorporate personalized medicine into multidisciplinary care pathways for breast cancer patients.

Examine current research and debate surrounding surgical and radiation de-escalation and apply shared decision-making principles to optimize patient-centered outcomes in early-stage breast cancer.

Interpret clinical trial designs and outcomes data from recent breast cancer studies and critically appraise their relevance and applicability to individual practice settings.

Identify barriers and facilitators to implementing new technologies and therapies in daily practice, and develop strategies to overcome challenges related to access, equity, and workflow integration.